title: Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine.
abstract: The aim of the present study was to develop proliposomal formulations to enhance the oral bioavailability of exemestane by improving solubility, dissolution and/or intestinal permeability. Proliposomal powder formulations were prepared using different ratios of drug (exemestane), distearoyl-phosphatidylcholine (DSPC), cholesterol and dimyristoyl-phosphatidylglycerol (DMPG) by solvent evaporation method. The effect of phospholipid composition and drug:lipid ratio on in vitro performance of proliposomes was studied. Proliposomes were characterized for their particle size distribution, thermal characteristics by differential scanning calorimetry (DSC) and dissolution behavior. Further, the formulated proliposomes were subjected to in vitro permeation or transport studies using different models such as rat intestine, parallel artificial membrane permeability assay (PAMPA) and Caco-2 cell line. Proliposomes provided enhanced exemestane dissolution due to incorporation into the phospholipid bilayers and change in the physical state from crystalline to amorphous. The in vitro transport studies in rat intestine, PAMPA and Caco-2 models revealed that the proliposomes were successful in enhancing the permeation of exemestane. These proliposomal formulations of exemestane could provide improved oral bioavailability due to enhanced solubility, permeability and hence absorption.
authors.affiliation: College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA. phiremath@pharm-int.com
authors.forename: Praveen S
authors.initials: PS
authors.lastname: Hiremath
authors.forename: Kumaresh S
authors.initials: KS
authors.lastname: Soppimath
authors.forename: Guru V
authors.initials: GV
authors.lastname: Betageri
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000730:Androstadienes / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D000818:Animals; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D018938:Caco-2 Cells; D002784:Cholesterol; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007422:Intestines / Q000737:chemistry; D008081:Liposomes / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics*; D008567:Membranes, Artificial; D010316:Particle Size; D010539:Permeability; D010713:Phosphatidylcholines; D010743:Phospholipids; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D004337:Drug Carriers; D008081:Liposomes; D008567:Membranes, Artificial; D010713:Phosphatidylcholines; D010743:Phospholipids; D002784:Cholesterol; C056516:exemestane